-
1.发明申请公开(公告)号：US20060281122A1
公开(公告)日：2006-12-14
申请号：US11449195
申请日：2006-06-08
申请人： Barbara Bryant , Andrew Damokosh , George Mulligan
发明人： Barbara Bryant , Andrew Damokosh , George Mulligan
IPC分类号： C12Q1/68 , G06Q10/00 , G01N33/574 , G06Q50/00
CPC分类号： C12Q1/6886 , A61K31/69 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57426 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N2800/44 , G06F19/20 , G06F19/24 , G06Q20/40 , G06Q50/22 , Y02A90/22 , Y02A90/26
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
摘要翻译： 本发明涉及可用于确定癌症患者在治疗前是否具有临床响应或对治疗方案无反应的预测标志物的鉴定。 特别地，本发明涉及预测标记的某些个体和/或组合的用途，其中预测标记物的表达与对治疗方案的反应性或非反应性相关。 因此，通过检查包含标志物组的个体预测标记和/或预测标记的表达水平，可以确定治疗剂或试剂组合是否最有可能降低临床中肿瘤的生长速率 设置。
-
2.发明申请公开(公告)号：US20080064055A1
公开(公告)日：2008-03-13
申请号：US11891213
申请日：2007-08-09
申请人： Barbara Bryant , Andrew Damokosh , George Mulligan
发明人： Barbara Bryant , Andrew Damokosh , George Mulligan
IPC分类号： C12Q1/02 , G01N33/574
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
摘要翻译： 本发明涉及可用于确定是否预期癌症患者将显示长期或短期存活时间的预测标志物的鉴定。 特别地，本发明涉及预测标记的某些个体和/或组合的用途，其中预测标记的表达与期望的短期或长期生存相关。 因此，通过检查包含标志物组的个体预测标记和/或预测标记的表达水平，可以确定预测的患者存活。
-
3.发明授权公开(公告)号：US09500656B2
公开(公告)日：2016-11-22
申请号：US11891213
申请日：2007-08-09
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
摘要翻译： 本发明涉及可用于确定是否预期癌症患者将显示长期或短期存活时间的预测标志物的鉴定。 特别地，本发明涉及预测标记的某些个体和/或组合的用途，其中预测标记的表达与期望的短期或长期生存相关。 因此，通过检查包含标志物组的个体预测标记和/或预测标记的表达水平，可以确定预测的患者存活。
-
4.发明申请Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy 审中-公开用于蛋白酶体抑制治疗的患者的鉴定，评估和治疗方法公开(公告)号：US20090181393A1
公开(公告)日：2009-07-16
申请号：US12316756
申请日：2008-12-16
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57484 , A61K38/05 , C07K14/47 , C12Q1/6883 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/574 , G01N2333/8107 , G01N2500/04 , Y02A90/22 , Y02A90/26
摘要： The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
摘要翻译： 本发明涉及鉴定可用于确定癌症患者在治疗前是否具有临床响应或对治疗方案无反应的标志物。 特别地，本发明涉及标记物的某些组合的用途，其中标志物的表达与包含蛋白酶体抑制的治疗方案的反应性或非反应性相关。 因此，通过检查单个标记物和包含标记物组的标记物的表达水平，可以确定治疗剂或试剂组合是否最有可能降低临床环境中肿瘤的生长速率。
-
5.发明申请公开(公告)号：US20130013334A1
公开(公告)日：2013-01-10
申请号：US13600260
申请日：2012-08-31
IPC分类号： C40B30/04 , C40B40/10 , A61K38/02 , A61K31/10 , G06Q50/22 , A61K31/4015 , A61P35/00 , A61P35/02 , A61K31/704 , C40B40/06 , A61K31/336
CPC分类号： C12Q1/6886 , A61K31/69 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57426 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N2800/44 , G06F19/20 , G06F19/24 , G06Q20/40 , G06Q50/22 , Y02A90/22 , Y02A90/26
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
-
6.发明授权公开(公告)号：US08278038B2
公开(公告)日：2012-10-02
申请号：US11449195
申请日：2006-06-08
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61K31/69 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57426 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N2800/44 , G06F19/20 , G06F19/24 , G06Q20/40 , G06Q50/22 , Y02A90/22 , Y02A90/26
摘要： The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
摘要翻译： 本发明涉及可用于确定癌症患者在治疗前是否具有临床响应或对治疗方案无反应的预测标志物的鉴定。 特别地，本发明涉及预测标记的某些个体和/或组合的用途，其中预测标记物的表达与对治疗方案的反应性或非反应性相关。 因此，通过检查包含标志物组的个体预测标记和/或预测标记的表达水平，可以确定治疗剂或试剂组合是否最有可能降低临床中肿瘤的生长速率 设置。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.031 秒)
